Clinical trials: Nervous System Disorder
Mild Cognitive Impairment, Cognitive Decline
Exercise in Adults With Mild Memory Problems
This study evaluates the effects of physical exercise on cognition, functional status, brain atrophy and blood flow, and cerebrospinal fluid biomarkers of Alzheimer's disease in adults with a mild memory impairment.
- Conditions
- Mild Cognitive Impairment, Cognitive Decline, Memory Impairment
- Trial name
- EXERT (NCT02814526)
- Testing
- Aerobic exercise, Stretching/balance/range of motion exercise
- Where
- 14 sites in United States
- Volunteers
- 296 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Fibromyalgia
Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia
The purpose of this study is to evaluate the durability of effect of milnacipran for the treatment of fibromyalgia in patients receiving long-term milnacipran treatment and to characterize the effects of milnacipran on multiple…
- Trial name
- NCT01014585
- Testing
- Milnacipran
- Where
- 58 sites in United States
- Volunteers
- 340 people
- Sponsor
- Forest Laboratories
Insomnia
A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)
The purpose of this trial is to investigate the efficacy, safety and tolerability of esmirtazapine (Org 50081) compared to placebo in patients with chronic primary insomnia.
- Trial name
- NCT00506389
- Testing
- Esmirtazapine
- Volunteers
- 419 people
- Sponsor
- Merck Sharp & Dohme LLC
Brain and Central Nervous System Tumors, Sarcoma
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
RATIONALE: Vatalanib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00348790
- Testing
- vatalanib
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Northwestern University
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis
Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
The purpose of this study is to determine a safe dose of BPX-501 gene modified T cells infused after a haplo-identical stem cell transplant to facilitate engraftment and the safety of Rimiducid (AP1903) on day 7 to prevent GVHD.
- Conditions
- Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies
- Trial name
- NCT02231710
- Testing
- BPX-501 and Rimiducid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Bellicum Pharmaceuticals
Fibromyalgia
Cefaly® Device in the Treatment of Patients With Fibromyalgia.
The objective of this pilot open trial was to assess the efficacy and safety of external trigeminal nerve stimulation (e-TNS) with the Cefaly® device in fibromyalgia.
- Trial name
- NCT02546362
- Testing
- Cefaly
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Cefaly Technology
Delirium, Respiratory Depression
Acupuncture for Sedation in the Intensive Care Unit (ICU)
BACKGROUND Many patients in the trauma intensive care unit (TICU) require mechanical ventilation and sedation or anxiolysis. Mechanical ventilation means that a machine is helping a patient breathe if he can't breathe on his own.
- Conditions
- Delirium, Respiratory Depression, Overmedication
- Trial name
- NCT01362270
- Testing
- Verum Acupuncture
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Oregon Health and Science University
Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
This pivotal, phase 3 study is designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type 4 (MC4R) agonist, for the treatment of obesity and hyperphagia in participants with Bardet Biedl…
- Trial name
- NCT03746522
- Testing
- Setmelanotide
- Where
- 12 sites in United States, Canada and 4 more
- Volunteers
- 52 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Epilepsy
Non-Interventional Study With LYRICA (Pregabalin) In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency
The primary efficacy parameter will be the responder rate, defined as the proportion of subjects who had at least a 50% reduction in 28 day seizure rate during the maintenance phase
- Trial name
- NCT00684424
- Testing
- Non-Interventional Study
- Volunteers
- 199 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Essential Tremor
A Phase 2 RCT Study of CX-8998 for Essential Tremor
This is a multicenter, double-blind, placebo-controlled, parallel-group study consisting of a screening period of up to 4 weeks (with the exception of participants on primidone at baseline who will be allowed 6 weeks of screening…
- Trial name
- NCT03101241
- Testing
- CX-8998
- Where
- 22 sites in United States
- Volunteers
- 95 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis, Encephalitis
tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis
This research is being done to determine whether transcranial direct current stimulation (tDCS) can improve certain mental abilities in individuals with multiple sclerosis (MS) or encephalitis.
- Trial name
- NCT02538094
- Testing
- Anodal Transcranial direct current stimulation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Johns Hopkins University
Growth Hormone Deficiency With Pituitary Anomalies
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
The Macimorelin Growth Hormone Stimulation Test (GHST) will be compared with the Insulin Tolerance Test (ITT) in an open-label, randomized, 2-way crossover Trial.
- Trial name
- NCT02558829
- Testing
- Macimorelin, Insulin
- Where
- 27 sites in United States, Austria and 7 more
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- AEterna Zentaris
Meningococcal Meningitis, Human Papillomavirus Infection
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents
This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine when administered with Tdap and HPV vaccinations to healthy adolescents
- Conditions
- Meningococcal Meningitis, Human Papillomavirus Infection, Pertussis, Tetanus
- Trial name
- NCT00518180
- Testing
- Novartis Meningococcal ACWY Conjugate Vaccine, Tdap Vaccine
- Where
- Costa Rica
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Advanced Cancers
Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
This randomized phase II trial studies how well haloperidol with or without lorazepam works in reducing confusion, disorientation, and inability to think or remember clearly (delirium) in patients with cancer that has spread to…
- Trial name
- NCT01949662
- Testing
- Lorazepam, Haloperidol decanoate, Questionnaires
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- M.D. Anderson Cancer Center
Constipation, Parkinson's Disease
Lubiprostone as a Treatment for Constipation in Parkinson's Disease
Delayed colonic transient time secondary to a multi-degenerative process is the most likely cause of constipation in idiopathic PD.
- Trial name
- NCT00669461
- Testing
- Lubiprostone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Arkansas
Dyskinesia, Levodopa-Induced Dyskinesia (LID)
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed…
- Conditions
- Dyskinesia, Levodopa-Induced Dyskinesia (LID), Parkinson's Disease (PD)
- Trial name
- EASE LID 3 (NCT02274766)
- Testing
- ADS-5102
- Where
- 51 sites in United States, Austria and 3 more
- Volunteers
- 77 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Breast Cancer, Fatigue
Three Different Programs of Paced Breathing in Treating Hot Flashes in Women
RATIONALE: Paced breathing may be an effective way to reduce the number and severity of hot flashes in women who have survived breast cancer.
- Conditions
- Breast Cancer, Fatigue, Hot Flashes, Sleep Disorders
- Trial name
- NCT00569166
- Testing
- Paced breathing (15 min once daily, 6 breaths/min), Paced breathing (15 min twice daily, 6 breaths/min), Paced breathing (10 min once daily, 14 breaths/min)
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Mayo Clinic
Post Operative Delirium
Effect of Anesthesia on Post-operative Delirium in Elderly Patients Undergoing Hip Fracture Surgery
The purpose of this study is evaluate postoperative delirium after general anesthesia and regional anesthesia in elderly patients undergoing hip fracture surgery.
- Trial name
- RAGADelirium (NCT02213380)
- Testing
- method of anesthesia
- Where
- 13 sites in China
- Volunteers
- 950 people
- Sponsor
- Wenzhou Medical University
Blood Pressure, Hypertension
Sleep Duration and Blood Pressure During Sleep
The purpose of this study is to examine the impact that sleep duration has on blood pressure (BP) levels during sleep. The investigator will examine the effect of an 8-week sleep hygiene/extension intervention vs.
- Conditions
- Blood Pressure, Hypertension, Elevated Blood Pressure, Sleep
- Trial name
- NCT05062161
- Testing
- Sleep hygiene/extension intervention, Control care
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Columbia University
Acute Repetitive Seizures, Breakthrough Seizures
Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects
This is a 12 month safety study to evaluate the safety of repeated doses of NRL-1
- Trial name
- NCT02721069
- Testing
- NRL-1
- Where
- 5 sites in United States
- Volunteers
- 175 people
- Sponsor
- Neurelis, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.